Multiple Myeloma: Symptoms, Treatment, and Patient Care 骨髓瘤
Multiple myeloma is a type of blood cancer affecting plasma cells (a kind of white blood cell) in the bone marrow. In Multiple myeloma, abnormal plasma cells grow uncontrollably, crowding out normal blood cells and producing abnormal proteins that can damage organs.
Common Symptoms
Symptoms can vary, but often include:
Bone pain (especially back or ribs)
Frequent infections
Fatigue / weakness (from anemia)
High calcium levels → thirst, constipation, confusion
Kidney problems
Bone fractures (bones become weak)
A simple way doctors remember key features is “CRAB”:
Calcium elevated
Renal (kidney) damage
Anemia
Bone lesions
Treatment (depends on stage & patient health)
There is no single cure, but many effective treatments:
Targeted therapy
Drugs that attack cancer cells specifically
Example: Bortezomib
Immunotherapy
Helps the immune system fight cancer
Example: Daratumumab
Chemotherapy
Kills rapidly growing cells
Steroids
Reduce inflammation and help kill myeloma cells
Stem cell transplant
Replaces diseased bone marrow with healthy cells
CAR-T cell therapy
Advanced treatment using modified immune cells (used in some cases)
Radiation therapy
Used for localized bone pain or lesions
Patient Care (daily management)
Good care is essential alongside treatment:
Regular monitoring (blood tests, kidney function)
Prevent infections (vaccines, hygiene)
Bone care
Calcium/Vitamin D
Medications to strengthen bones
Pain management
Healthy diet & hydration
Light exercise to maintain strength
Emotional support (family, support groups)
Brief Summary
Multiple myeloma is a cancer of plasma cells that affects bones, blood, and kidneys. It causes symptoms like bone pain, fatigue, and infections. While not usually curable, modern treatments (targeted therapy, immunotherapy, transplant, CAR-T) can control the disease and improve quality of life. Proper medical care and lifestyle support are important for long-term management.
Here is a clear, up-to-date summary (2025–2026 data) on CAR-T therapy and other latest treatments for multiple myeloma:
🧬 Latest Treatment Advances in Multiple Myeloma (Focus on CAR-T)
⭐ 1. CAR-T Cell Therapy (Biggest Breakthrough)
CAR-T therapy uses a patient’s own immune T-cells, genetically engineered to attack myeloma cells (usually targeting BCMA).
💥 Current top CAR-T products
Idecabtagene vicleucel (Abecma)
Ciltacabtagene autoleucel (Carvykti)
📊 CAR-T Success Rates (Latest Clinical Trials 2025–2026)
🔹 Overall Response Rate (ORR)
~80%–100% in many modern trials
Some frontline/early use studies report ~97%–100% response
🔹 Deep response (very important)
Complete response / stringent complete response: ~60%–95%
Minimal residual disease (MRD) negativity: up to 90%+
👉 MRD negativity means no detectable cancer at ultra-sensitive levels.
📈 Survival Improvements
Recent large trials show:
Progression-free survival (PFS):
~18–50+ months depending on patient group
Some high-risk groups still progression-free at 2–3+ years in >70% cases
Long-term remission:
Many patients remain disease-free for years after a single infusion (especially earlier-line use)
🚀 Why CAR-T is becoming a game changer
Recent studies (ASH 2025) show:
CAR-T is moving from last-line therapy → earlier treatment line
When used earlier:
Higher response rates
Longer remission (PFS significantly improved)
Better immune recovery outcomes (Springer)
🧪 2. New CAR-T Innovations
🧬 Dual-target CAR-T
Targets 2 proteins instead of 1 (e.g., BCMA + GPRC5D)
Helps prevent relapse from “antigen escape”
🏠 “In vivo CAR-T” (experimental)
CAR-T cells are created inside the body (no lab manufacturing step)
🧊 Allogeneic (“off-the-shelf”) CAR-T
Donor-derived cells
Faster treatment availability
🧪 3. Bispecific Antibodies (Competing breakthrough)
These are “off-the-shelf” immune therapies (no cell collection needed).
Examples:
teclistamab (BCMA × CD3 class drugs)
Success rates:
ORR: ~60%–90%
Some newer combinations show >90% response
MRD negativity up to ~70–90% in selected studies (PMC)
⚖️ CAR-T vs Bispecific Antibodies
| Feature | CAR-T | Bispecific antibodies |
|---|---|---|
| Response rate | ⭐ 80–100% | 60–90% |
| Depth of remission | ⭐ Very deep (MRD− high) | High but slightly lower |
| Duration | ⭐ Often longer | Good but may require continuous dosing |
| Treatment style | One-time infusion | Ongoing injections |
⚠️ Limitations of CAR-T
Even with success:
Relapse can still occur (not a cure yet for most)
Side effects:
Cytokine release syndrome (CRS)
Neurotoxicity (usually manageable)
Expensive and complex manufacturing
🧭 Bottom line
CAR-T therapy is now one of the most powerful treatments in multiple myeloma
Modern trials show:
~80–100% response rates
Many patients achieving deep, long remissions
It is rapidly moving toward earlier-line and possibly curative intent strategies
Here is a clear, up-to-date comparison of FDA-approved CAR-T therapies for multiple myeloma (2025–2026), focusing on effectiveness, cost, and side effects.
🧬 FDA-Approved CAR-T Therapies for Multiple Myeloma
Currently, there are 2 FDA-approved CAR-T therapies:
1️⃣ Idecabtagene vicleucel (Abecma)
Approved: 2021
Target: BCMA (B-cell maturation antigen)
Used for: Relapsed/refractory multiple myeloma (after ≥2 prior therapies)
2️⃣ Ciltacabtagene autoleucel (Carvykti)
Approved: 2022
Target: BCMA (with dual binding sites → stronger binding)
Now increasingly used earlier in relapse (first or second relapse in many cases)
📊 Effectiveness Comparison
| Outcome | Abecma | Carvykti |
|---|---|---|
| Overall response rate | ~70–80% | 90–98% |
| Complete response (deep remission) | ~30–40% | 60–80% |
| Median progression-free survival | ~8–12 months | 18–24+ months |
| Long-term durable response (3–5 yrs) | Uncommon | Increasingly observed |
👉 Key takeaway:
Carvykti is currently the most potent CAR-T therapy in myeloma
Higher chance of deep and long-lasting remission
💰 Cost Comparison (U.S.)
| Item | Abecma | Carvykti |
|---|---|---|
| Drug price | ~$419,500 | ~$465,000 |
| Total treatment cost (hospital + care) | ~$500K–$750K+ | ~$500K–$800K+ |
👉 Notes:
Insurance (Medicare/private) often covers a large portion
Out-of-pocket costs vary widely depending on coverage
⚠️ Side Effects Comparison
Common to both CAR-T therapies
Cytokine Release Syndrome (CRS)
Fever, low blood pressure
Occurs in ~70–90% of patients (usually manageable)
Neurotoxicity (ICANS)
Confusion, speech difficulty, fatigue
~20–40% incidence
Low blood counts / infection risk
Differences
| Side effect profile | Abecma | Carvykti |
|---|---|---|
| CRS severity | Generally milder | More frequent / sometimes more intense |
| Neurotoxicity | Moderate | Slightly higher risk (including delayed neurotoxicity in some cases) |
| Overall safety | More stable | More intensive monitoring required |
👉 Summary:
Abecma = safer but less powerful
Carvykti = more effective but higher toxicity risk
🧾 Overall Clinical Takeaways
✔ Best efficacy
👉 Carvykti is currently the most effective FDA-approved CAR-T for multiple myeloma
✔ Best safety profile
👉 Abecma is slightly safer and more predictable
✔ Long-term outlook
CAR-T is no longer “last resort”
It is moving earlier in treatment lines
Some patients achieve multi-year remission without relapse
🚀 2025–2026 Key Trends
CAR-T being used earlier (1st or 2nd relapse instead of late-stage)
Higher response rates in earlier use (>90%)
Development of:
Dual-target CAR-T therapies
Off-the-shelf “in vivo CAR-T” approaches
CAR-T combined with monoclonal antibodies or bispecific antibodies
📌 Simple Summary
Two FDA-approved CAR-T options: Abecma and Carvykti
Carvykti = higher response (up to ~98%) and deeper remission
Abecma = safer but slightly less effective
Both are expensive (~$500K–$800K total treatment cost)
Major side effects include CRS and neurotoxicity, usually manageable in specialized centers
If you want, I can also break down:
“Which CAR-T is better for specific patient profiles (age, kidney function, frailty)”
or “CAR-T vs bispecific antibodies (new major competitor in 2026)”
Here is a focused, up-to-date overview of CAR-T development and treatment for multiple myeloma in China (2024–2026 landscape):
CAR-T Therapy for Multiple Myeloma in China (Latest Progress)
China is currently one of the global leaders in CAR-T development for multiple myeloma, with rapid clinical expansion, domestic innovation, and earlier regulatory approval compared with many regions.
🧬 1. Approved CAR-T Therapies in China
China has already approved multiple BCMA-targeted CAR-T therapies for relapsed/refractory multiple myeloma:
⭐ Key approved products
Ciltacabtagene autoleucel (Carvykti)
Approved by China NMPA (2024–2025)
One of the most effective BCMA CAR-T therapies globally
Used after ≥3 prior treatments (National Medical Products Administration)
Idecabtagene vicleucel (Abecma)
Also used in China (imported access / clinical programs)
Zevorcabtagene autoleucel (zevor-cel)
Fully human BCMA CAR-T developed in China
Approved in 2024 for relapsed/refractory MM (PubMed)
LCAR-B38M (Legend Biotech / Nanjing)
One of the earliest Chinese CAR-T platforms
High response rates in Chinese trials
📊 2. Treatment Outcomes in China (Real-world + trials)
China’s CAR-T data for multiple myeloma is among the strongest worldwide:
💥 Response rates
Overall response rate (ORR):
~80% to 96%+ in Chinese clinical studies
Some trials report up to ~96% response in heavily pretreated patients (Springer Link)
Complete response (CR / sCR):
~50%–80% depending on product and stage
MRD negativity (deep remission):
Up to ~70%–90% in best-performing studies
📈 Durability
Many patients achieve 1–3+ years of remission
Some remain disease-free longer after single infusion therapy
🧪 3. Major Innovations Coming from China
China is not only using CAR-T—it is actively pushing next-generation designs:
🧬 (1) Dual-target CAR-T
Targets two antigens (e.g., BCMA + GPRC5D)
Helps reduce relapse from antigen escape
Early studies show very high response rates (some approaching near-universal responses in small cohorts reported in conferences)
🧬 (2) Fully human CAR-T
Example: zevor-cel
Designed to reduce immune rejection and improve durability
🧬 (3) Earlier-line use
China is actively testing CAR-T:
In earlier relapse (2nd line instead of 4th–5th line)
Even moving toward front-line combination trials
➡️ This is important because:
Earlier use = deeper remission
Better immune recovery
Longer progression-free survival
🧪 (4) Combination strategies
CAR-T is being combined with:
Proteasome inhibitors
Immunomodulatory drugs (lenalidomide class)
Bispecific antibodies
Goal: extend remission and reduce relapse
🏥 4. Why China is advancing fast
⚙️ Key advantages
Large patient population → faster trials
Strong government and biotech investment
Many dedicated CAR-T manufacturing centers
Lower cost vs US/EU
💰 Cost advantage (typical range)
~$60,000–$200,000 USD in China
Often significantly lower than US pricing (~$400,000+)
⚖️ 5. CAR-T in China vs global standards
China is now on par with US/EU in efficacy for BCMA CAR-T, and in some areas:
Faster trial enrollment
More aggressive innovation (dual-target, earlier-line use)
Broader real-world access programs
⚠️ 6. Remaining challenges
Despite progress:
Relapse still occurs (not a permanent cure for most patients yet)
Cytokine release syndrome (CRS) remains a major side effect
Manufacturing time still weeks
Long-term safety monitoring ongoing (rare secondary malignancy risk being studied globally)
🧭 Bottom line
China has become a global hub for multiple myeloma CAR-T therapy, with:
✔ Multiple approved BCMA CAR-T products
✔ ~80–96% response rates in clinical studies
✔ Rapid innovation in dual-target and fully human CAR-T
✔ Increasing use earlier in the disease course
✔ Expanding real-world treatment access
China is currently one of the global leaders in CAR-T therapy for multiple myeloma, but different cities have different strengths. The “best center” depends on whether you prioritize clinical excellence, innovation, or international patient services.
Below is a clear comparison of the top hubs: Beijing vs Shanghai vs Shenzhen (Greater Bay Area ecosystem).
🇨🇳 1. Shanghai — 🧬 Most advanced for research + clinical innovation
⭐ Overall: #1 in scientific leadership for multiple myeloma CAR-T
Key centers:
Ruijin Hospital (Shanghai Jiao Tong University School of Medicine)
Fudan University Shanghai Cancer Center
Jiahui International Hospital (private international option)
Why Shanghai leads:
1. Strongest hematology research base in China
Ruijin is consistently ranked among the top 1–3 hematology centers nationwide
Major contributor to CAR-T trial design and next-gen targets (BCMA, GPRC5D)
2. Most advanced CAR-T clinical trials
First-in-China studies for:
dual-target CAR-T
next-generation BCMA therapies
Reported very high response rates (~90%+ in some MM trials) (China Care Health Tours)
3. Best integration of research + clinical care
Strong collaboration between labs and hospital wards
Frequent participation in global trials
➜ Bottom line:
👉 Shanghai = most cutting-edge science and innovation for multiple myeloma CAR-T
🇨🇳 2. Beijing — 🏥 Most structured, high-volume clinical systems
Key centers:
Peking Union Medical College Hospital
Beijing GoBroad Hospital
Lu Daopei Hospital system
Why Beijing stands out:
1. Extremely high treatment volume
GoBroad alone has performed thousands of CAR-T treatments (CancerCareE)
2. Very standardized treatment pathways
Strong ICU support for complications (CRS, neurotoxicity)
Highly protocol-driven care → predictable outcomes
3. Strong private + public ecosystem
Public hospitals: academic excellence
Private groups (GoBroad, Lu Daopei): faster access, more “service-oriented”
4. Excellent for complex or high-risk patients
Especially relapsed/refractory myeloma cases with complications
➜ Bottom line:
👉 Beijing = most established “industrial-scale” CAR-T treatment system
🇨🇳 3. Shenzhen / Greater Bay Area — 🚀 Fast-growing private biotech hub
Key centers:
GoBroad Shenzhen branches (part of national network)
Emerging CAR-T biotech hospitals (Guangzhou–Shenzhen corridor)
Why Shenzhen is rising:
1. Strong biotech + industry integration
Close connection to biotech companies and manufacturing
Faster access to new CAR-T products (clinical + early commercial use)
2. More private, international-style hospitals
More English-friendly services in some institutions
Faster admission compared to public hospitals
3. Innovation focus rather than academic leadership
Strong in:
manufacturing improvements
new CAR-T constructs
combination immunotherapy trials
➜ Bottom line:
👉 Shenzhen = fast access + biotech-driven CAR-T innovation, but less academic depth than Shanghai
🧭 Final Comparison (Simple View)
| City | Strength | Best For |
|---|---|---|
| Shanghai | 🧬 Most advanced research + trials | Cutting-edge CAR-T, complex myeloma, best science |
| Beijing | 🏥 Highest treatment volume + structure | Standardized care, high-risk patients, reliability |
| Shenzhen / GBA | 🚀 Fast, private, biotech-driven | Quick access, newer therapies, convenience |
🧠 Practical takeaway
If you want best possible scientific innovation → Shanghai (Ruijin/Fudan)
If you want most experienced large-scale treatment system → Beijing (GoBroad/PUMCH)
If you want fast access + private hospital convenience → Shenzhen/GBA
Below is a practical, evidence-based breakdown (2025–2026 data) answering your four questions about CAR-T therapy for multiple myeloma in China.
🇨🇳 1. Which hospital has the highest CAR-T success rate for Multiple Myeloma?
🥇 Top performer: Shanghai Ruijin Hospital (Shanghai Jiao Tong University)
Why it is considered #1 for multiple myeloma CAR-T:
One of the earliest and most experienced BCMA CAR-T programs in China
Very strong published outcomes in relapsed/refractory multiple myeloma
Uses structured multidisciplinary care (hematology + ICU + immunology teams)
📊 Reported outcomes (real-world + clinical data):
Overall response rate (ORR): ~90%+ in selected CAR-T trials
Deep response (CR/sCR): ~60–80%
MRD negativity: very high in newer protocols
Some newer GPRC5D/dual-target trials reported ~94%+ response rates (CAR T Therapy China)
👉 Ruijin is especially strong in:
Patients who failed previous BCMA CAR-T
Complex or high-risk relapsed multiple myeloma
🥈 Other top-tier centers
Beijing GoBroad Hospital (Beijing)
Extremely high-volume CAR-T center
Strong ICU + complication management system
Very standardized “industrial-scale” treatment model
👉 Best for safety + complex patients + logistics
Beijing Lu Daopei Hospital
One of the earliest CAR-T pioneers in China
Very experienced in blood cancers overall
👉 Best for relapsed hematologic malignancies broadly
Shenzhen / Greater Bay Area hospitals
Faster access and newer biotech integration
👉 Best for speed and convenience, not top academic leadership
💰 2. Cost differences between Beijing, Shanghai, Shenzhen
💵 Typical total CAR-T cost (international patients)
| City | Estimated Total Cost | Notes |
|---|---|---|
| 🇨🇳 Shanghai | $70,000 – $180,000 | Highest-tier academic hospitals, slightly higher pricing |
| 🇨🇳 Beijing | $60,000 – $160,000 | More competition → slightly lower average cost |
| 🇨🇳 Shenzhen / GBA | $55,000 – $150,000 | Private/biotech-driven, sometimes faster access |
Key cost drivers:
CAR-T product type (domestic vs imported like Carvykti)
ICU stay (major cost variation factor)
Whether patient enters a clinical trial (can reduce cost significantly)
📌 China is still ~50–70% cheaper than US/EU overall (China Health Guide)
🧭 3. How international patients get admitted (step-by-step)
This is the real clinical pathway used in Shanghai/Beijing centers:
Step 1 — Medical record submission (online)
Diagnosis reports (bone marrow biopsy, FISH, PET-CT)
Prior treatment history
Blood work
Step 2 — Doctor review (1–2 weeks)
Hematology team evaluates:
eligibility (relapsed/refractory MM)
organ function (heart, kidney, liver)
Step 3 — Pre-approval + treatment plan
Hospital decides:
CAR-T product type (BCMA / dual-target)
whether patient enters clinical trial or commercial pathway
Step 4 — Invitation letter issued
Needed for medical visa (S1/S2 visa)
Step 5 — Travel + admission
Patient arrives in China (usually Shanghai or Beijing)
Baseline tests repeated in hospital
Step 6 — Leukapheresis (T-cell collection)
Blood drawn → T-cells extracted
Step 7 — CAR-T manufacturing (2–4 weeks)
Cells engineered in lab
Step 8 — Bridging therapy (if needed)
Low-dose chemo to control disease while waiting
Step 9 — Infusion + monitoring (2–4 weeks inpatient)
CAR-T infusion
ICU monitoring for CRS / neurotoxicity
Step 10 — Follow-up
3, 6, 12-month monitoring
🧬 4. Is Shanghai CAR-T close to a “functional cure” today?
🧠 Short answer:
👉 Sometimes yes — but not yet consistently for all patients
📊 What “functional cure” means in CAR-T myeloma:
No detectable disease (MRD-negative)
Long remission without continuous therapy
Disease may still exist at microscopic level but controlled long-term
🧬 Shanghai (Ruijin & Fudan data reality):
What is promising:
Some patients achieve:
MRD negativity rates up to 80–90% in best cohorts
3–5+ year durable remissions in a subset
Newer CAR-T (dual-target, GPRC5D) shows very deep responses
What is NOT yet a cure:
Relapse still occurs in many patients over time
Median durability varies:
~1.5 to 4+ years depending on risk group and CAR-T type (Orieast)
🧭 Realistic conclusion:
🟢 Shanghai CAR-T status today:
✔ Some patients: functional long-term remission (near cure behavior)
✔ Best-in-world early deep response rates
⚠ Not yet a universal cure for all multiple myeloma patients
🧠 Final takeaway
🥇 Best CAR-T success in multiple myeloma: Shanghai Ruijin Hospital
🏥 Best system + safety + scale: Beijing GoBroad / Lu Daopei
🚀 Fastest access: Shenzhen / Greater Bay Area
💰 Cost: ~$55K–$180K depending on city + trial access
🧬 Functional cure: possible in a subset, especially MRD-negative responders, but not guaranteed yet
以下是關於**多發性骨髓瘤（Multiple Myeloma）**的簡要中文（繁體）說明：
一、什麼是多發性骨髓瘤
多發性骨髓瘤是一種發生在骨髓中的癌症，源於漿細胞（負責製造抗體）異常增生。這些異常細胞會：
影響正常血液細胞生成
破壞骨骼
產生異常蛋白（M蛋白），影響腎臟等器官
二、常見症狀
可用「CRAB」記憶：
C（高血鈣）：口渴、噁心、便秘、意識混亂
R（腎功能異常）：疲倦、水腫、尿量變化
A（貧血）：頭暈、虛弱、氣喘
B（骨病變）：骨痛（常見於背部、肋骨）、骨折
其他症狀：
易感染
體重減輕
三、治療方式
依病情分期與患者狀況而定，主要包括：
標靶治療
常用藥物如 Bortezomib、Lenalidomide免疫治療
單株抗體（如 Daratumumab）
CAR-T 細胞療法（新興療法，對復發患者有效）
化療與類固醇
抑制癌細胞生長幹細胞移植
適合體力較佳患者，可延長緩解期放射治療
緩解局部骨痛
四、患者照護重點
預防感染：勤洗手、避免人群
骨骼保護：避免跌倒、必要時使用護具
腎臟保護：多喝水、避免腎毒性藥物
營養與休息：均衡飲食、適度活動
定期追蹤：監測血液與腎功能
五、簡短總結
多發性骨髓瘤是一種骨髓癌，主要影響骨骼與免疫系統。常見症狀包括骨痛、貧血與腎功能問題。雖然目前尚難完全治癒，但透過標靶、免疫治療與幹細胞移植，可有效控制病情並延長壽命。
以下是截至2025–2026年最新研究，關於**CAR‑T 細胞療法在多發性骨髓瘤**的治療進展與成功率（用簡單重點整理）：
🧬 一、CAR-T 最新成功率（最重要）
👉 整體來看，療效非常高，尤其在復發或難治患者
✔ 1. 反應率（是否有效）
70–90%患者有反應 (ScienceDirect)
新研究甚至達：
96–98%反應率（部分試驗） (International Myeloma Foundation)
97%整體反應率、68%完全緩解 (UT MD Anderson)
👉 簡單說：
👉「10個人中約7–9人會明顯改善」
✔ 2. 完全緩解（幾乎看不到癌）
約 50–70%可達深度緩解 (Israeli Hospitals)
最新試驗：
完全緩解率可達 68% (UT MD Anderson)
新型CAR-T甚至接近 90%以上（早期治療） (Springer)
✔ 3. 存活與控制時間
1年無惡化率：約79% (UT MD Anderson)
18個月：約66%仍控制住 (UT MD Anderson)
總存活率：1–1.5年達90–95% (UT MD Anderson)
👉 長期數據：
約 33%患者可維持5年以上無復發 (Mount Sinai Reports)
🚀 二、2025–2026重大突破
1️⃣ CAR-T開始提前使用（不是最後才用）
以前：最後線治療
現在：可能提早到初期使用
效果：
反應率接近 100%
完全緩解率 94–97% (Springer)
👉 意義：
👉「越早用，效果越好」
2️⃣ 更持久的效果（接近“功能性治癒”）
有些患者：
5年以上無病存活 (Mount Sinai Reports)
研究顯示：
成功與患者免疫系統品質有關 (Mount Sinai Health System)
3️⃣ 新技術方向（正在快速進步）
雙靶點CAR-T（更精準） (International Myeloma Foundation)
體內製造CAR-T（in vivo） → 未來可能更方便 (International Myeloma Foundation)
CAR-T + 抗體/免疫藥物聯合（提升持久性）
⚠️ 三、目前限制（很重要）
雖然效果很好，但仍有挑戰：
❗ 1. 仍可能復發
多數患者在 1–3年內復發 (PMC)
❗ 2. 不是人人有效
少數人（約10–30%）反應不佳
❗ 3. 副作用
發燒（細胞激素風暴）
神經副作用
（但安全性正在改善）
🧾 四、簡單總結（給病人/家屬）
👉 CAR-T 是目前最強的多發性骨髓瘤新療法之一：
✔ 成功率：約70–95%有效
✔ 完全緩解：約50–70%
✔ 部分患者：可能5年以上不復發
✔ 趨勢：越早用 → 效果越好
👉 但：
仍未完全治癒
可能復發，需要後續治療
以下整理目前FDA已批准、用於多發性骨髓瘤的CAR-T療法（截至2025–2026），重點比較成功率／費用／副作用，讓你一眼看懂：
🧬 一、目前FDA核准的CAR-T（骨髓瘤）
目前只有2種：
1️⃣ Idecabtagene vicleucel（Abecma）
2021年核准（首個CAR-T） (U.S. Food and Drug Administration)
適用：復發/難治（至少2線治療後） (The ASCO Post)
2️⃣ Ciltacabtagene autoleucel（Carvykti）
2022年核准 (U.S. Food and Drug Administration)
已擴展到較早期（甚至第一次復發） (The ASCO Post)
👉 結論：
👉 目前只有這兩款，但Carvykti療效更強（最新共識）
📊 二、療效（成功率）比較
| 指標 | Abecma | Carvykti |
|---|---|---|
| 整體反應率 | 約 70–80% | 約 90–98% |
| 完全緩解率 | 約 30–40% | 約 60–80% |
| 無惡化存活 | 約 8–12個月 | 約 18–24個月+ |
| 長期（≥3–5年） | 少數 | 明顯較多 |
👉 解讀：
Carvykti 效果顯著更強、持久更長
已逐漸成為「主流首選CAR-T」
（以上來自多項臨床試驗整合）
💰 三、費用比較（美國）
CAR-T是目前最昂貴治療之一：
| 項目 | Abecma | Carvykti |
|---|---|---|
| 藥物價格 | 約 $419,500 | 約 $465,000 |
| 總費用（含住院） | 約 $500K–$750K+ | 約 $500K–$800K+ |
👉 重點：
Medicare/保險通常可部分覆蓋
仍需自付數萬美元（依保險）
⚠️ 四、副作用比較（關鍵）
共同副作用（兩者都有）
細胞激素風暴（CRS）
發燒、低血壓
發生率：70–90%
神經毒性（ICANS）
意識混亂、說話困難
約 20–40%
感染風險
免疫力下降
差異重點
| 項目 | Abecma | Carvykti |
|---|---|---|
| CRS嚴重度 | 較低 | 較高（但可控） |
| 神經副作用 | 較常見 | 特殊延遲神經毒性（需注意） |
| 整體安全性 | 穩定 | 稍高風險但療效更好 |
👉 簡單說：
Abecma：較安全
Carvykti：效果更強，但需更密切監測
🧾 五、整體比較（最實用結論）
👉 如果簡單選：
✔ 追求療效（長期控制）
→ 👉 Carvykti（目前最佳）✔ 年長或體力較弱
→ 👉 Abecma（較安全）
📌 六、最新趨勢（非常重要）
CAR-T 正在往更早期使用
Carvykti已：
可在「第一次復發」就用 (The ASCO Post)
未來方向：
雙靶點CAR-T
CAR-T + 抗體聯合
「一次治療接近長期控制」
✅ 最簡單總結（給病人）
👉 目前2種CAR-T：
Abecma：較安全，但效果普通
Carvykti：效果最強（目前首選）
👉 成功率：
約 70–98%有效
Carvykti明顯更好
👉 最大問題：
費用高
仍可能復發
如果你需要，我可以幫你再做一個更實用版本：
👉「哪一類病人最適合做CAR-T（年齡/腎功能/復發次數）」
👉 或「2026最新非CAR-T替代療法（雙抗體 vs CAR-T）」
以下是你問題的繁體中文完整整理（2025–2026最新CAR-T在中國多發性骨髓瘤應用）：
🇨🇳 1. 哪一家醫院在多發性骨髓瘤CAR-T成功率最高？
🥇 第一名：上海瑞金醫院（上海瑞金醫院）
為什麼被認為最強：
中國最早、最成熟的BCMA CAR-T中心之一
多發性骨髓瘤臨床研究量全國領先
擁有完整「血液科 + ICU + 免疫治療」整合系統
📊 臨床效果（綜合研究數據）：
整體反應率（ORR）：約 90% 以上
完全緩解（CR / sCR）：約 60%–80%
MRD陰性率（深度緩解）：非常高（新方案可達80–90%）
👉 特別優勢：
適合復發/難治型多發性骨髓瘤
對「已用過CAR-T失敗」患者仍有方案
🥈 其他頂尖中心
🏥 北京高博醫院（北京高博醫院）
CAR-T治療量非常大（屬「工業級規模」）
ICU與副作用（CRS、神經毒性）管理成熟
👉 強項：安全性 + 重症管理 + 經驗最豐富
🏥 北京陸道培醫院（北京陸道培醫院）
中國CAR-T先驅之一
血液腫瘤整體經驗非常豐富
🏥 深圳／大灣區醫療中心
偏向快速治療 + 生技導向
新CAR-T較容易較早取得
💰 2. 北京 vs 上海 vs 深圳：費用差異
💵 CAR-T總費用（國際患者常見範圍）
| 城市 | 費用（美元） | 特點 |
|---|---|---|
| 🇨🇳 上海 | $70,000 – $180,000 | 學術頂尖，略貴 |
| 🇨🇳 北京 | $60,000 – $160,000 | 規模大、競爭多，價格稍低 |
| 🇨🇳 深圳／大灣區 | $55,000 – $150,000 | 私立多、速度快 |
💡 影響價格關鍵：
CAR-T產品（國產 vs 國際如Carvykti）
是否進入臨床試驗（可能大幅減費）
ICU住院天數（副作用影響很大）
📌 中國整體仍比美國便宜約 50%–70%
🧭 3. 外國患者如何在中國接受CAR-T（流程）
📌 Step 1：提交醫療資料
骨髓報告
基因檢測（FISH等）
PET-CT影像
過往治療紀錄
📌 Step 2：醫師評估（1–2週）
醫院判斷：
是否為復發/難治多發性骨髓瘤
心臟、腎臟、肝功能是否可承受治療
📌 Step 3：治療方案確認
BCMA CAR-T 或雙靶點CAR-T
是否進入臨床試驗
📌 Step 4：發出邀請函
用於申請中國醫療簽證
📌 Step 5：入境住院評估
再次檢查（確保安全）
📌 Step 6：採集T細胞（白血球分離）
提取患者免疫細胞
📌 Step 7：CAR-T製備（2–4週）
基因工程改造T細胞
📌 Step 8：橋接治療（如需要）
控制腫瘤增長
📌 Step 9：CAR-T回輸 + 住院觀察（2–4週）
監測CRS（細胞激素風暴）
監測神經副作用
📌 Step 10：長期追蹤
3、6、12個月檢查
🧬 4. 上海CAR-T是否接近「功能性治癒」？
🧠 簡單答案：
👉 部分患者可以接近，但尚未普遍達到真正治癒
📊 上海瑞金 / Fudan數據現況：
✔ 非常理想結果：
MRD陰性率可達 80–90%（新一代CAR-T）
部分患者可維持 3–5年以上無復發
⚠ 仍然存在限制：
部分患者仍會復發（特別是高風險基因型）
平均緩解時間約：
1.5–4年以上不等
🧭 結論：
🟢 現實狀態
✔ 有些患者可達「長期無病狀態（接近功能性治癒）」
✔ 上海在全球CAR-T中屬最先進之一
❗ 但仍不是所有人都能被「完全治癒」
🧠 最重要總結
🥇 最佳成功率（多發性骨髓瘤CAR-T）：上海瑞金醫院
🏥 最大規模與安全系統：北京高博 / 陸道培
🚀 最快治療通道：深圳 / 大灣區
💰 費用：$55,000 – $180,000
🧬 功能性治癒：部分患者可達，但尚未普遍實現
You May Like:
No comments:
Post a Comment